Wells Fargo’s HilleVax HLVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-7,360
| Closed | -$14.6K | – | 7219 |
|
|
2025
Q2 | $14.6K | Sell |
7,360
-10,782
| -59% | -$19.7K | ﹤0.01% | 5856 |
|
|
2025
Q1 | $26.3K | Buy |
18,142
+401
| +2% | +$741 | ﹤0.01% | 5613 |
|
|
2024
Q4 | $36.7K | Buy |
17,741
+4,229
| +31% | +$7.94K | ﹤0.01% | 5579 |
|
|
2024
Q3 | $23.8K | Buy |
13,512
+418
| +3% | +$1.07K | ﹤0.01% | 5589 |
|
|
2024
Q2 | $189K | Buy |
13,094
+4,174
| +47% | +$57.4K | ﹤0.01% | 4547 |
|
|
2024
Q1 | $148K | Buy |
8,920
+1,148
| +15% | +$18.4K | ﹤0.01% | 4659 |
|
|
2023
Q4 | $125K | Buy |
7,772
+2,794
| +56% | +$37.1K | ﹤0.01% | 4770 |
|
|
2023
Q3 | $67K | Sell |
4,978
-3,227
| -39% | -$45.4K | ﹤0.01% | 5018 |
|
|
2023
Q2 | $141K | Buy |
8,205
+5,084
| +163% | +$78.8K | ﹤0.01% | 4802 |
|
|
2023
Q1 | $51.6K | Buy |
+3,121
| New | +$49.9K | ﹤0.01% | 5148 |
|
|
2022
Q4 | – | Sell |
-71
| Closed | -$1K | – | 7571 |
|
|
2022
Q3 | $1K | Sell |
71
-124
| -64% | -$1.8K | ﹤0.01% | 6355 |
|
|
2022
Q2 | $2K | Buy |
+195
| New | +$2.32K | ﹤0.01% | 6326 |
|
Wells Fargo's HLVX Position: Q3 2025 in Review
Wells Fargo sold out of HilleVax (HLVX) in Q3 2025, closing a stake of 7,360 shares — an estimated $14.6K sold.
Wells Fargo first reported a position in HLVX in Q2 2022 and held it in 12 quarters. The position peaked at $189K in Q2 2024. 1 fund tracked by Wall St. Rank holds HLVX as of Q3 2025.
- Wells Fargo reported no remaining HilleVax position as of Q3 2025 after selling out during the quarter.
- Wells Fargo sold 7,360 HilleVax shares in Q3 2025, an estimated $14.6K.
- Wells Fargo first reported a position in HilleVax in Q2 2022 and held it in 12 quarters.
- Wells Fargo's HilleVax position peaked at $189K in Q2 2024.
- 1 fund tracked by Wall St. Rank held HilleVax as of Q3 2025.
Based on Wells Fargo's 13F filing for Q3 2025, filed 13 Nov 2025.